AngioDynamics (ANGO)
Market Price (10/5/2026): $15.11 | Market Cap: $630.1 MilSector: Health Care | Industry: Health Care Equipment
AngioDynamics (ANGO)
Market Price (10/5/2026): $15.11Market Cap: $630.1 MilSector: Health CareIndustry: Health Care Equipment
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Low stock price volatilityVol 12M is 42% Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Oncology Treatments, and Targeted Therapies. | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -22 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -7.0% Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 204x Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -1.5% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -11% Key risksANGO key risks include [1] its ongoing challenges in achieving consistent profitability and positive free cash flow and [2] the need to successfully scale new product platforms, Show more. |
| Low stock price volatilityVol 12M is 42% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Oncology Treatments, and Targeted Therapies. |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -22 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -7.0% |
| Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 204x |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -1.5% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -11% |
| Key risksANGO key risks include [1] its ongoing challenges in achieving consistent profitability and positive free cash flow and [2] the need to successfully scale new product platforms, Show more. |
Qualitative Assessment
AI Analysis | Feedback
AngioDynamics (ANGO) stock has gained about 15% since 6/30/2026 because of the following key factors:
1. Strong Fiscal Year 2026 Performance Exceeded Expectations. AngioDynamics reported robust financial results for fiscal year 2026, which ended May 31, 2026, surpassing analyst estimates for both adjusted earnings per share (EPS) and revenue, announced on July 14, 2026. The company posted an adjusted loss per share of $0.07, outperforming the consensus estimate of a $0.09 loss, while revenue reached $86.6 million, approximately 8% above the $80.24 million forecast. This performance highlighted successful execution of its strategic shift towards higher-margin medical technology products and significantly improved profitability, with full-year adjusted EBITDA rising sharply to $13.2 million from $7.6 million in the prior year.
2. Significant Growth in Med Tech Segment and Key Product Platforms. The company demonstrated substantial growth in its Med Tech segment, a strategic focus area, which saw sales increase 16.7% year-over-year in fiscal Q4 2026 to $41.8 million and accounted for 47% of total revenue for the full fiscal year 2026. Key product lines were strong contributors: NanoKnife sales surged by 64.5% to $11.8 million, AlphaVac grew 38.4%, and Auryon increased by 14.4% in fiscal Q4 2026. AngioDynamics also projected continued momentum for fiscal year 2027, guiding Med Tech sales to grow between 12% and 15%.
Show more
AngioDynamics (ANGO) stock has gained about 15% since 6/30/2026 because of the following key factors:
1. Strong Fiscal Year 2026 Performance Exceeded Expectations. AngioDynamics reported robust financial results for fiscal year 2026, which ended May 31, 2026, surpassing analyst estimates for both adjusted earnings per share (EPS) and revenue, announced on July 14, 2026. The company posted an adjusted loss per share of $0.07, outperforming the consensus estimate of a $0.09 loss, while revenue reached $86.6 million, approximately 8% above the $80.24 million forecast. This performance highlighted successful execution of its strategic shift towards higher-margin medical technology products and significantly improved profitability, with full-year adjusted EBITDA rising sharply to $13.2 million from $7.6 million in the prior year.
2. Significant Growth in Med Tech Segment and Key Product Platforms. The company demonstrated substantial growth in its Med Tech segment, a strategic focus area, which saw sales increase 16.7% year-over-year in fiscal Q4 2026 to $41.8 million and accounted for 47% of total revenue for the full fiscal year 2026. Key product lines were strong contributors: NanoKnife sales surged by 64.5% to $11.8 million, AlphaVac grew 38.4%, and Auryon increased by 14.4% in fiscal Q4 2026. AngioDynamics also projected continued momentum for fiscal year 2027, guiding Med Tech sales to grow between 12% and 15%.
3. Expanded Market Access and Regulatory Approvals for NanoKnife. A significant catalyst was the finalization of a local coverage determination by Palmetto GBA, effective July 5, 2026, which covered NanoKnife IRE for eligible Medicare patients in prostate and liver cancer, expanding market access and reimbursement. Further boosting future growth prospects, AngioDynamics received FDA Investigational Device Exemption (IDE) approval for the RELIEF study, evaluating NanoKnife IRE for the treatment of benign prostatic hyperplasia, indicating new therapeutic applications.
4. Favorable Analyst Sentiment and Increased Price Targets. Analysts reacted positively to the company's performance and strategic direction during the period. For instance, HC Wainwright raised its price target for AngioDynamics from $16.00 to $19.00 on July 15, 2026. By September 18, 2026, the overall analyst community maintained a "Strong Buy" consensus rating, with an average price target of $20.00, representing a potential upside of over 30% from the share price of $15.37 at that time.
Show less
Stock Movement Drivers
Fundamental Drivers
The 16.1% change in ANGO stock from 6/30/2026 to 10/4/2026 was primarily driven by a 14.1% change in the company's P/S Multiple.| (LTM values as of) | 6302026 | 10042026 | Change |
|---|---|---|---|
| Stock Price ($) | 13.01 | 15.11 | 16.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 314 | 320 | 2.1% |
| P/S Multiple | 1.7 | 2.0 | 14.1% |
| Shares Outstanding (Mil) | 42 | 42 | -0.3% |
| Cumulative Contribution | 16.1% |
Market Drivers
6/30/2026 to 10/4/2026| Return | Correlation | |
|---|---|---|
| ANGO | 16.1% | |
| Market (SPY) | 3.1% | 24.8% |
| Sector (XLV) | 4.7% | 15.8% |
Fundamental Drivers
The 32.9% change in ANGO stock from 3/31/2026 to 10/4/2026 was primarily driven by a 28.0% change in the company's P/S Multiple.| (LTM values as of) | 3312026 | 10042026 | Change |
|---|---|---|---|
| Stock Price ($) | 11.37 | 15.11 | 32.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 307 | 320 | 4.2% |
| P/S Multiple | 1.5 | 2.0 | 28.0% |
| Shares Outstanding (Mil) | 42 | 42 | -0.4% |
| Cumulative Contribution | 32.9% |
Market Drivers
3/31/2026 to 10/4/2026| Return | Correlation | |
|---|---|---|
| ANGO | 32.9% | |
| Market (SPY) | 18.6% | 21.1% |
| Sector (XLV) | 13.8% | 34.2% |
Fundamental Drivers
The 35.3% change in ANGO stock from 9/30/2025 to 10/4/2026 was primarily driven by a 25.7% change in the company's P/S Multiple.| (LTM values as of) | 9302025 | 10042026 | Change |
|---|---|---|---|
| Stock Price ($) | 11.17 | 15.11 | 35.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 292 | 320 | 9.5% |
| P/S Multiple | 1.6 | 2.0 | 25.7% |
| Shares Outstanding (Mil) | 41 | 42 | -1.7% |
| Cumulative Contribution | 35.3% |
Market Drivers
9/30/2025 to 10/4/2026| Return | Correlation | |
|---|---|---|
| ANGO | 35.3% | |
| Market (SPY) | 16.5% | 28.8% |
| Sector (XLV) | 20.9% | 27.1% |
Fundamental Drivers
The 106.7% change in ANGO stock from 9/30/2023 to 10/4/2026 was primarily driven by a 130.2% change in the company's P/S Multiple.| (LTM values as of) | 9302023 | 10042026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.31 | 15.11 | 106.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 339 | 320 | -5.5% |
| P/S Multiple | 0.9 | 2.0 | 130.2% |
| Shares Outstanding (Mil) | 40 | 42 | -5.0% |
| Cumulative Contribution | 106.7% |
Market Drivers
9/30/2023 to 10/4/2026| Return | Correlation | |
|---|---|---|
| ANGO | 106.7% | |
| Market (SPY) | 86.2% | 27.7% |
| Sector (XLV) | 35.2% | 28.1% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ANGO Return | 80% | -50% | -43% | 17% | 40% | 21% | 2% |
| Peers Return | 13% | -9% | 11% | 10% | 4% | -12% | 15% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 12% | 104% |
Monthly Win Rates [3] | |||||||
| ANGO Win Rate | 67% | 25% | 33% | 50% | 67% | 56% | |
| Peers Win Rate | 47% | 50% | 57% | 53% | 55% | 38% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 44% | |
Max Drawdowns [4] | |||||||
| ANGO Max Drawdown | -21% | -59% | -60% | -34% | -35% | -27% | |
| Peers Max Drawdown | -24% | -38% | -28% | -21% | -25% | -31% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: BSX, MDT, PEN, MMSI, TFX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 10/2/2026 (YTD)
How Low Can It Go
| Event | ANGO | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -23.1% | -18.8% |
| % Gain to Breakeven | 30.0% | 23.1% |
| Time to Breakeven | 85 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -29.1% | -9.5% |
| % Gain to Breakeven | 41.0% | 10.5% |
| Time to Breakeven | 397 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -36.3% | -6.7% |
| % Gain to Breakeven | 56.9% | 7.1% |
| Time to Breakeven | 951 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -34.4% | -33.7% |
| % Gain to Breakeven | 52.5% | 50.9% |
| Time to Breakeven | 195 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -10.1% | -19.2% |
| % Gain to Breakeven | 11.2% | 23.8% |
| Time to Breakeven | 11 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -11.4% | -3.7% |
| % Gain to Breakeven | 12.9% | 3.9% |
| Time to Breakeven | 55 days | 6 days |
In The Past
AngioDynamics's stock fell -23.1% during the 2025 US Tariff Shock. Such a loss loss requires a 30.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | ANGO | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -23.1% | -18.8% |
| % Gain to Breakeven | 30.0% | 23.1% |
| Time to Breakeven | 85 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -29.1% | -9.5% |
| % Gain to Breakeven | 41.0% | 10.5% |
| Time to Breakeven | 397 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -36.3% | -6.7% |
| % Gain to Breakeven | 56.9% | 7.1% |
| Time to Breakeven | 951 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -34.4% | -33.7% |
| % Gain to Breakeven | 52.5% | 50.9% |
| Time to Breakeven | 195 days | 140 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -33.1% | -12.2% |
| % Gain to Breakeven | 49.4% | 13.9% |
| Time to Breakeven | 155 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -29.0% | -6.8% |
| % Gain to Breakeven | 40.8% | 7.3% |
| Time to Breakeven | 141 days | 15 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -48.9% | -53.4% |
| % Gain to Breakeven | 95.8% | 114.4% |
| Time to Breakeven | 2142 days | 1085 days |
In The Past
AngioDynamics's stock fell -23.1% during the 2025 US Tariff Shock. Such a loss loss requires a 30.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About AngioDynamics (ANGO)
AngioDynamics, Inc. (ANGO) is a medical technology company specializing in the design, manufacture, and sale of advanced medical, surgical, and diagnostic devices. The company's core business revolves around providing solutions for treating peripheral vascular disease, facilitating vascular access, and supporting oncology and surgical procedures. Its innovative product portfolio enables professional healthcare providers to diagnose and treat a variety of conditions across these key medical areas.
The company offers a range of sophisticated products, including ablation systems like NanoKnife, solero microwave, and radiofrequency ablation products, which are utilized for the surgical ablation of soft tissues and both cancerous and benign tumors. For vascular access, AngioDynamics provides a comprehensive line of peripherally inserted central catheters (PICC), midline catheters, implantable ports, and dialysis catheters under brands such as BioFlo and Xcela, which are critical for delivering short-term drug therapies. Additionally, the company develops devices for thrombus management, atherectomy, and general peripheral interventions, alongside essential tools like angiographic catheters and guidewires.
AngioDynamics' primary customers are professional healthcare providers within hospitals and medical facilities globally. Its diverse clientele includes interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses. The company distributes its products through both direct sales forces and established distributor relationships, ensuring its specialized medical devices reach the practitioners who need them for patient care.
AI Analysis | Feedback
AngioDynamics is like a specialized Boston Scientific, focusing on peripheral vascular disease treatments and unique tumor ablation technologies.
AngioDynamics is like a more specialized Becton Dickinson (BD), providing advanced tools for vascular access, disease management, and targeted tumor destruction.
AI Analysis | Feedback
- NanoKnife Ablation Systems: Devices designed for the surgical ablation of soft tissues.
- Microwave & Radiofrequency Ablation Systems: Systems used for ablating solid cancerous or benign tumors.
- Oncology & Surgical Support Products: Includes tract sealant systems, endorectal balloons, and vaginal balloon packing systems for use in oncology and surgical settings.
- Diagnostic & Interventional Devices: Products such as angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits.
- Vascular Interventions & Therapies Products: Devices addressing thrombus management, atherectomy, peripheral vascular disease, and venous insufficiency.
- Vascular Access Devices: A range of peripherally inserted central catheters (PICC), midline catheters, implantable ports, and dialysis catheters for delivering short-term drug therapies into the central venous system.
AI Analysis | Feedback
- Hospitals and Clinics: These are the primary institutional customers where professional healthcare providers such as interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses utilize AngioDynamics' products for patient treatment.
- Medical Distributors: AngioDynamics sells its products through "distributor relationships," indicating that medical distributors are direct customers who then facilitate the sale and delivery of these products to various healthcare providers and facilities.
- Specialized Healthcare Facilities and Group Practices: This category includes specialized centers focusing on areas like peripheral vascular disease, oncology, or surgical settings, which may operate independently or as part of larger networks and directly purchase devices for their specific needs.
AI Analysis | Feedback
AI Analysis | Feedback
Jim Clemmer, President and Chief Executive Officer
Jim Clemmer joined AngioDynamics in April 2016 and brings over 25 years of leadership within the healthcare industry. Prior to AngioDynamics, he served as president of the $1.8 billion medical supplies segment at Covidien plc., where he directed strategic and day-to-day operations for global business divisions. He also managed global manufacturing, research and development, operational excellence, and business development. Before Covidien, Clemmer was group president at Kendall Healthcare, where he managed the U.S. business across five divisions and developed the strategic plan for the Medical Supplies segment before its spin-off from Tyco. He began his career at Sage Products, Inc. Clemmer currently serves on the Board of Directors for AngioDynamics and Lantheus Medical Imaging.
Stephen A. Trowbridge, Executive Vice President and Chief Financial Officer
Stephen A. Trowbridge was appointed Executive Vice President and Chief Financial Officer in February 2020, having served as Interim Chief Financial Officer since October 2019. He joined AngioDynamics in June 2008 as Corporate Counsel and subsequently served as Senior Vice President and General Counsel. Prior to AngioDynamics, Mr. Trowbridge served as Corporate Counsel at Philips Healthcare and Intermagnetics General Corporation. He began his career with Cadwalader, Wickersham & Taft LLP in the firm's Mergers and Acquisitions and Securities Group.
Laura Piccinini, Senior Vice President/General Manager, Cardiovascular & International
Laura Piccinini joined AngioDynamics in June 2021, bringing more than 25 years of experience in leadership roles in the Medical Device/Technology industry, with an extensive background in respiratory care. Most recently, she served as CEO and a member of the Board of Directors for Respiratory Motion, Inc. She was also Global Head of Commercial Operations for the Implants business unit at Nobel Biocare Systems (Danaher Company/Envista IPO). Earlier in her career, Ms. Piccinini served as President of EMEA at both Covidien and Stryker.
Chad T. Campbell, Senior Vice President and General Manager for AngioDynamics' Oncology and Interventional Devices Global Business Units
Chad T. Campbell joined AngioDynamics in May 2016. In his role, he oversees global commercialization of the Oncology and Interventional Devices global business unit portfolios. Mr. Campbell joined AngioDynamics from Medtronic, where he served as Vice President of Marketing for the Patient Care and Safety business. He previously served as the Vice President of Marketing for the SharpSafety business at Covidien (Medtronic). During his tenure at Covidien, Mr. Campbell also held roles including Director of Marketing, Area Vice President of Sales, and other sales & marketing positions.
AI Analysis | Feedback
Key Risks for AngioDynamics
- Regulatory Hurdles and Reimbursement Challenges: As a medical device company, AngioDynamics is heavily reliant on obtaining and maintaining regulatory approvals for its diverse product portfolio, including devices for peripheral vascular disease, vascular access, and oncology applications. Changes in regulatory policies by bodies such as the FDA, or in domestic and foreign healthcare reforms and government regulations, could delay product introductions or necessitate costly compliance measures. Furthermore, evolving healthcare reimbursement policies and pricing pressures from group purchasing organizations directly impact the market acceptance and profitability of AngioDynamics' products, affecting demand and revenue generation.
- Intense Competition and Rapid Technological Obsolescence: AngioDynamics operates in highly competitive markets with numerous participants, some of whom possess substantially greater financial and technological resources. The company faces ongoing pressure from competitors' technological advancements, new product introductions, and aggressive pricing strategies. The failure to continuously innovate, develop new products, or gain market acceptance for its offerings could lead to a loss of market share and reduced sales.
- Product Liability Claims and Recalls: Given that AngioDynamics designs, manufactures, and sells medical, surgical, and diagnostic devices used in critical healthcare settings, there is an inherent risk of product defects or malfunctions. Such issues could lead to patient injury, costly product recalls, and significant product liability claims, which could severely impact the company's financial performance, reputation, and ability to sell its products.
AI Analysis | Feedback
AI Analysis | Feedback
AngioDynamics (ANGO) operates in several medical device markets, with the following addressable market sizes identified for their main products and services:
- Microwave Tissue Ablation Systems: The global microwave ablation market was valued at approximately USD 437.1 million in 2024 and is projected to reach USD 962.1 million by 2030. North America held the largest revenue share of 31.2% in the global market in 2024.
- Radiofrequency Ablation Products (Oncology/Tumor Ablation): The global radiofrequency ablation tumor ablation market was valued at USD 703.7 million in 2025 and is estimated to grow to USD 2,051.1 million by 2033. North America was the largest revenue-generating market in 2025. The broader global radiofrequency ablation devices market (including various applications) was estimated at USD 4.3 billion in 2022 and is projected to reach USD 10.5 billion by 2030.
- Thrombus Management: The global thrombin market was valued at USD 662.96 million in 2024 and is poised to grow to USD 1,073.4 million by 2033. North America is the largest market, accounting for approximately 45% of the global share.
- Atherectomy Devices: The global atherectomy devices market size was USD 794.6 million in 2024 and is expected to grow to USD 1.6 billion by 2034. The U.S. atherectomy devices market alone was valued at USD 432.6 million in 2024. North America dominates the atherectomy devices market, holding a 42.4% share in 2025.
- Peripheral Products (Peripheral Vascular Disease Treatment): The global peripheral arterial disease treatment market was valued at USD 2.95 billion in 2024 and is projected to reach USD 6.11 billion by 2034. North America dominated this market with a 39% share in 2024. The global peripheral vascular devices market was valued at USD 9.55 billion in 2025 and is projected to reach USD 13.22 billion by 2031.
- Venous Insufficiency: The chronic venous insufficiency treatment market in the 7MM (United States, EU4, UK, and Japan) was estimated at USD 2,652 million in 2025 and is projected to reach USD 5,951 million by 2034. The U.S. accounted for the largest market size for chronic venous insufficiency in 2023.
- Peripherally Inserted Central Catheters (PICC): The global peripherally inserted central catheters market size was valued at USD 1.25 billion in 2025 and is projected to grow to USD 3.23 billion by 2034. North America was the largest region in the PICC market in 2025 and is expected to hold the largest share of 46.65% in 2023.
- Midline Catheters: The global midline catheter market size was estimated at USD 3.01 billion in 2024 and is projected to reach USD 4.74 billion by 2032. North America dominated the midline catheters market with the largest revenue share of 40.31% in 2024.
- Implantable Ports: The global adult implantable port market size was USD 3.53 billion in 2025 and is projected to grow to USD 7.01 billion by 2032. North America is expected to dominate the adult implantable port market with a market share percentage valuation of around 37%. Another estimate for the global implantable port market was slightly over USD 370 million in 2023, expected to reach about USD 450 million.
- Dialysis Catheters: The global dialysis catheters market size was valued at around USD 1 billion in 2023. The hemodialysis catheters segment recorded USD 927.7 million in 2023. The global hemodialysis catheters market size was USD 1.14 billion in 2025 and is predicted to increase to approximately USD 2.08 billion by 2035. North America's dialysis catheters market accounted for USD 408.8 million in revenue in 2023.
AI Analysis | Feedback
AngioDynamics (ANGO) is anticipated to drive future revenue growth over the next 2-3 years through several key strategies and product performances:
-
Strong Performance and Expansion of Med Tech Portfolio: The company's Med Tech segment, identified as its growth engine, is expected to continue driving revenue. This includes sustained growth from the Auryon peripheral atherectomy platform, which has consistently shown double-digit year-over-year growth. The thrombus management platform, particularly the AlphaVac mechanical thrombectomy system, is also a significant contributor, with AlphaVac revenues increasing substantially and projected to surpass AngioVac in the coming years due to a larger market opportunity for pulmonary embolism (PE). AngioDynamics is further investing in this area by expanding its dedicated PE sales force and achieving regulatory milestones like IDE approvals for APEX-Return and PAVE studies, and 510(k) clearance for a modified AlphaVac system. Additionally, the NanoKnife irreversible electroporation platform is experiencing strong growth, largely fueled by increased prostate procedures and the implementation of a new CPT code, which is expected to further boost adoption.
-
International Market Expansion: AngioDynamics is actively pursuing and experiencing growth in international markets. The company's international business demonstrated double-digit growth, with efforts like the third international clinical life symposium leading to increased interest in its Med Tech products globally. Notably, the CE Mark approval for its Auryon platform has facilitated its contribution to international revenue. The company is strategically focused on expanding its products geographically.
-
Customer Base Expansion and Increased Utilization: Growth in AngioDynamics' customer base, particularly within Office-Based Labs (OBLs) and hospital settings, is expected to enhance revenue. This expansion, coupled with increased utilization of its products in existing accounts, positively impacts average selling prices (ASP) and overall revenue.
-
Strategic Portfolio Shift and Pricing Actions: The company has undertaken a strategic reshaping of its portfolio, moving away from slower-growth, commodity-oriented markets to focus on higher-growth, higher-margin Med Tech categories. This strategic shift aims to improve the overall revenue mix. Furthermore, AngioDynamics has implemented pricing actions that have contributed to gross margin improvement and are expected to continue enhancing revenue.
AI Analysis | Feedback
Share Repurchases
- AngioDynamics announced an Equity Buyback program for $15 million worth of its shares on July 16, 2024.
Capital Expenditures
- Capital expenditures were $4.30 million in fiscal year 2022, $3.81 million in fiscal year 2023, and $2.52 million in fiscal year 2024.
- In the second quarter of fiscal year 2026 (ended November 30, 2025), capital expenditures were $4.5 million.
- AngioDynamics is committed to investing in research and development initiatives, targeting approximately 10% of sales going forward to support the long-term growth of its Med Tech segment.
Peer Outperformance in Health Care Equipment
| Ticker | Name | Rev Growth 3Y Avg | P/E | 1Y | 3Y | 5Y | 5Y Gap |
|---|---|---|---|---|---|---|---|
| ANGO | AngioDynamics | -1.5% | -17.2x | 29.8% | 111.3% | -45.1% | — |
| RVTY | Revvity | 0.9% | 71.2x | 61.6% | 43.3% | -9.8% | +35pp |
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 12.8% | 43.2% | 91.3% | CAH 414% · MCK 366% · COR 175% |
| Health Care Services | 20 | 18.8% | 36.3% | 9.1% | HIMS 295% · RDNT 144% · DGX 81% |
| Managed Health Care | 8 | 25.4% | -8.6% | 4.2% | OSCR 92% · HQY 38% · ELV 11% |
| Health Care Facilities | 24 | -2.1% | 5.0% | -3.6% | THC 291% · NHC 272% · ENSG 131% |
| Health Care Equipment ← | 50 | -8.9% | -0.2% | -16.2% | POCI 11050% · UFPT 374% · GKOS 253% |
| Pharmaceuticals | 62 | -7.4% | -2.8% | -30.9% | INDV 1117% · ETON 1046% · LQDA 953% |
| Health Care Supplies | 12 | 21.5% | -4.9% | -37.5% | LNTH 296% · HAE 52% · MMSI 19% |
| Life Sciences Tools & Services | 109 | -5.7% | -11.3% | -66.7% | SNWV 1867% · NTRA 269% · MEDP 210% |
| Health Care Technology | 21 | -35.8% | -55.3% | -79.1% | SPOK 79% · HSTM 10% · VEEV -2% |
| Biotechnology | 362 | -18.3% | -24.6% | -79.3% | CELZ 1252% · ELVN 1139% · DNTH 1108% |
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| AngioDynamics Earnings Notes | 12/16/2025 | |
| AngioDynamics Stock Jump Looks Great, But How Secure Is That Gain? | 10/17/2025 | |
| Day 8 of Gains Streak for AngioDynamics Stock with 17% Return (vs. 16% YTD) [9/3/2025] | 09/04/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 86.01 |
| Mkt Cap | 9.0 |
| Rev LTM | 1,604 |
| Op Inc LTM | 194 |
| FCF LTM | 271 |
| FCF 3Y Avg | 287 |
| CFO LTM | 343 |
| CFO 3Y Avg | 367 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 11.9% |
| Rev Chg 3Y Avg | 7.8% |
| Rev Chg Q | 11.6% |
| QoQ Delta Rev Chg LTM | 2.8% |
| Op Inc Chg LTM | 12.6% |
| Op Inc Chg 3Y Avg | 14.8% |
| Op Mgn LTM | 12.6% |
| Op Mgn 3Y Avg | 12.1% |
| QoQ Delta Op Mgn LTM | -0.1% |
| CFO/Rev LTM | 19.9% |
| CFO/Rev 3Y Avg | 18.9% |
| FCF/Rev LTM | 13.5% |
| FCF/Rev 3Y Avg | 12.7% |
Segment Financials
Revenue by Segment| $ Mil | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Med Device | 170 | 166 | 198 | 242 | 238 |
| Med Tech | 150 | 127 | 106 | 97 | 79 |
| Total | 320 | 292 | 304 | 339 | 316 |
| $ Mil | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|
| Vascular | 13 | 8 | ||
| Oncology and Surgery | 0 | 4 | ||
| Corporate | -16 | |||
| Access | 8 | 10 | ||
| Oncology/Surgery | 0 | -5 | ||
| Peripheral Vascular | 12 | 11 | ||
| Total | -3 | 12 | 21 | 16 |
| $ Mil | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|
| Vascular | 482 | 294 | ||
| Oncology and Surgery | 239 | 143 | ||
| Access | 148 | 138 | ||
| Oncology/Surgery | 142 | 145 | ||
| Peripheral Vascular | 134 | 125 | ||
| Total | 722 | 437 | 424 | 409 |
Price Behavior
| Market Price | $15.11 | |
| Market Cap ($ Bil) | 0.6 | |
| First Trading Date | 06/01/2004 | |
| Distance from 52W High | -6.3% | |
| 50 Days | 200 Days | |
| DMA Price | $15.40 | $12.45 |
| DMA Trend | up | up |
| Distance from DMA | -1.9% | 21.4% |
| 3M | 1YR | |
| Volatility | 34.3% | 42.1% |
| Downside Capture | 74.81 | 69.60 |
| Upside Capture | 136.60 | 87.87 |
| Correlation (SPY) | 25.4% | 29.3% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.04 | 0.40 | 0.79 | 0.72 | 0.95 | 1.01 |
| Up Beta | -0.15 | 0.23 | -0.63 | 0.94 | 1.11 | 0.91 |
| Down Beta | 1.13 | 1.32 | 0.93 | 0.84 | 0.99 | 1.12 |
| Up Capture | -29% | 44% | 161% | 77% | 101% | 111% |
| Bmk +ve Days | 6 | 16 | 27 | 66 | 132 | 424 |
| Stock +ve Days | 11 | 23 | 37 | 66 | 127 | 371 |
| Down Capture | 22% | 16% | 71% | 27% | 78% | 100% |
| Bmk -ve Days | 16 | 26 | 37 | 60 | 120 | 328 |
| Stock -ve Days | 11 | 17 | 25 | 58 | 121 | 362 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ANGO | |
|---|---|---|---|---|
| ANGO | 36.7% | 42.4% | 0.84 | - |
| Sector ETF (XLV) | 17.4% | 15.7% | 0.82 | 28.1% |
| Equity (SPY) | 16.2% | 13.0% | 0.88 | 28.9% |
| Gold (GLD) | 6.8% | 29.6% | 0.22 | 12.7% |
| Commodities (DBC) | 44.9% | 20.8% | 1.67 | -18.7% |
| Real Estate (VNQ) | 1.5% | 13.6% | -0.15 | 24.3% |
| Bitcoin (BTCUSD) | -28.9% | 44.3% | -0.64 | 13.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ANGO | |
|---|---|---|---|---|
| ANGO | -8.6% | 54.0% | 0.03 | - |
| Sector ETF (XLV) | 6.4% | 15.2% | 0.23 | 31.4% |
| Equity (SPY) | 13.1% | 17.2% | 0.58 | 31.2% |
| Gold (GLD) | 18.4% | 18.9% | 0.79 | 8.7% |
| Commodities (DBC) | 10.3% | 19.6% | 0.41 | 3.1% |
| Real Estate (VNQ) | 0.7% | 18.8% | -0.07 | 28.2% |
| Bitcoin (BTCUSD) | 14.6% | 52.2% | 0.45 | 15.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ANGO | |
|---|---|---|---|---|
| ANGO | -1.2% | 47.9% | 0.15 | - |
| Sector ETF (XLV) | 10.4% | 16.7% | 0.50 | 34.5% |
| Equity (SPY) | 15.3% | 17.9% | 0.72 | 36.3% |
| Gold (GLD) | 11.5% | 16.4% | 0.57 | 6.8% |
| Commodities (DBC) | 8.2% | 18.1% | 0.37 | 9.2% |
| Real Estate (VNQ) | 4.2% | 20.7% | 0.16 | 32.4% |
| Bitcoin (BTCUSD) | 64.1% | 66.2% | 1.04 | 12.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 8/14/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 7/14/2026 | 1.8% | 7.3% | 23.3% |
| 4/2/2026 | -13.7% | -15.5% | -6.5% |
| 1/6/2026 | -13.5% | -23.1% | -20.7% |
| 10/2/2025 | 6.1% | 0.5% | 9.7% |
| 7/15/2025 | -10.2% | -6.6% | -8.2% |
| 4/2/2025 | 12.4% | -6.8% | -4.9% |
| 1/8/2025 | 37.7% | 29.5% | 17.4% |
| 10/3/2024 | -16.7% | -20.5% | -12.5% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 12 | 11 | 10 |
| # Negative | 12 | 13 | 14 |
| Median Positive | 11.7% | 12.7% | 17.3% |
| Median Negative | -12.7% | -15.5% | -14.9% |
| Max Positive | 37.7% | 29.5% | 27.0% |
| Max Negative | -27.0% | -34.8% | -37.2% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 7/14/2026 | 1.8% | 7.3% | 23.3% |
| 4/2/2026 | -13.7% | -15.5% | -6.5% |
| 1/6/2026 | -13.5% | -23.1% | -20.7% |
| 10/2/2025 | 6.1% | 0.5% | 9.7% |
| 7/15/2025 | -10.2% | -6.6% | -8.2% |
| 4/2/2025 | 12.4% | -6.8% | -4.9% |
| 1/8/2025 | 37.7% | 29.5% | 17.4% |
| 10/3/2024 | -16.7% | -20.5% | -12.5% |
| 7/16/2024 | 26.6% | 20.2% | 27.0% |
| 4/4/2024 | 5.3% | 12.7% | 0.0% |
| 1/5/2024 | -19.9% | -21.8% | -24.4% |
| 10/4/2023 | -2.6% | -2.8% | -17.8% |
| 7/12/2023 | -1.7% | -2.0% | -17.3% |
| 3/30/2023 | -27.0% | -23.6% | -33.3% |
| 1/5/2023 | 13.7% | -2.1% | -1.3% |
| 10/6/2022 | -19.5% | -34.8% | -37.2% |
| 7/12/2022 | -0.1% | 3.7% | 17.0% |
| 4/7/2022 | 9.1% | 7.4% | -8.7% |
| 1/6/2022 | -11.8% | -20.4% | -25.8% |
| 9/30/2021 | 11.0% | 14.5% | 21.8% |
| 7/13/2021 | -3.4% | -12.8% | -5.1% |
| 3/30/2021 | 7.9% | 15.5% | 17.2% |
| 1/7/2021 | 14.7% | 14.8% | 24.7% |
| 9/29/2020 | 19.4% | 11.1% | 2.2% |
| SUMMARY STATS | |||
| # Positive | 12 | 11 | 10 |
| # Negative | 12 | 13 | 14 |
| Median Positive | 11.7% | 12.7% | 17.3% |
| Median Negative | -12.7% | -15.5% | -14.9% |
| Max Positive | 37.7% | 29.5% | 27.0% |
| Max Negative | -27.0% | -34.8% | -37.2% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 05/31/2026 | 07/14/2026 | 10-K |
| 02/28/2026 | 04/02/2026 | 10-Q |
| 11/30/2025 | 01/06/2026 | 10-Q |
| 08/31/2025 | 10/02/2025 | 10-Q |
| 05/31/2025 | 07/18/2025 | 10-K |
| 02/28/2025 | 04/02/2025 | 10-Q |
| 11/30/2024 | 01/08/2025 | 10-Q |
| 08/31/2024 | 10/03/2024 | 10-Q |
| 05/31/2024 | 07/25/2024 | 10-K |
| 02/29/2024 | 04/09/2024 | 10-Q |
| 11/30/2023 | 01/08/2024 | 10-Q |
| 08/31/2023 | 10/05/2023 | 10-Q |
| 05/31/2023 | 08/03/2023 | 10-K |
| 02/28/2023 | 03/31/2023 | 10-Q |
| 11/30/2022 | 01/06/2023 | 10-Q |
| 08/31/2022 | 10/11/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 05/31/2026 | 07/14/2026 | 10-K |
| 02/28/2026 | 04/02/2026 | 10-Q |
| 11/30/2025 | 01/06/2026 | 10-Q |
| 08/31/2025 | 10/02/2025 | 10-Q |
| 05/31/2025 | 07/18/2025 | 10-K |
| 02/28/2025 | 04/02/2025 | 10-Q |
| 11/30/2024 | 01/08/2025 | 10-Q |
| 08/31/2024 | 10/03/2024 | 10-Q |
| 05/31/2024 | 07/25/2024 | 10-K |
| 02/29/2024 | 04/09/2024 | 10-Q |
| 11/30/2023 | 01/08/2024 | 10-Q |
| 08/31/2023 | 10/05/2023 | 10-Q |
| 05/31/2023 | 08/03/2023 | 10-K |
| 02/28/2023 | 03/31/2023 | 10-Q |
| 11/30/2022 | 01/06/2023 | 10-Q |
| 08/31/2022 | 10/11/2022 | 10-Q |
| 05/31/2022 | 07/22/2022 | 10-K |
| 02/28/2022 | 04/07/2022 | 10-Q |
| 11/30/2021 | 01/07/2022 | 10-Q |
| 08/31/2021 | 09/30/2021 | 10-Q |
| 05/31/2021 | 07/27/2021 | 10-K |
| 02/28/2021 | 03/31/2021 | 10-Q |
| 11/30/2020 | 01/08/2021 | 10-Q |
| 08/31/2020 | 10/07/2020 | 10-Q |
| 05/31/2020 | 08/10/2020 | 10-K |
| 02/29/2020 | 04/08/2020 | 10-Q |
| 11/30/2019 | 01/08/2020 | 10-Q |
| 08/31/2019 | 10/04/2019 | 10-Q |
Recent Forward Guidance
Updated 10/4/2026Latest: Q4 2026 Earnings Reported 7/14/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2027 Net Sales | Reported | 336.00 Mil | 338.50 Mil | 341.00 Mil | 7.6% | Higher New | Actual: 314.50 Mil for 2026 | |
| 2027 Med Tech Net Sales Growth | Reported | 12.0% | 13.5% | 15.0% | -2.5% | Lower New | Actual: 16.0% for 2026 | |
| 2027 Med Device Net Sales Growth | Reported | 0.0% | -1.0% | Lower New | Actual: 1.0% for 2026 | |||
| 2027 Gross Profit | Calculated | 181.44 Mil | 184.48 Mil | 187.55 Mil | Rev x Gross Margin | |||
| 2027 Gross Margin | Reported | 54.0% | 54.5% | 55.0% | 0.0% | Same New | Actual: 54.5% for 2026 | |
| 2027 Adjusted EBITDA | Reported | 13.00 Mil | 14.50 Mil | 16.00 Mil | 31.8% | Higher New | Actual: 11.00 Mil for 2026 | |
| 2027 Adjusted EPS | Reported | -0.29 | -0.27 | -0.24 | 0.0% | Same New | Actual: -0.27 for 2026 | |
Prior: Q3 2026 Earnings Reported 4/2/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Net Sales | Reported | 313.50 Mil | 314.50 Mil | 315.50 Mil | 0.5% | Raised | Guidance: 313.00 Mil for 2026 | |
| 2026 Med Tech Net Sales Growth | Reported | 15.0% | 16.0% | 17.0% | 1.0% | Raised | Guidance: 15.0% for 2026 | |
| 2026 Med Device Net Sales Growth | Reported | 1.0% | 0.5% | Raised | Guidance: 0.5% for 2026 | |||
| 2026 Gross Profit | Calculated | 167.72 Mil | 171.40 Mil | 175.10 Mil | Rev x Gross Margin | |||
| 2026 Gross Margin | Reported | 53.5% | 54.5% | 55.5% | 0 | Affirmed | Guidance: 54.5% for 2026 | |
| 2026 Adjusted EBITDA | Reported | 10.00 Mil | 11.00 Mil | 12.00 Mil | 22.2% | Raised | Guidance: 9.00 Mil for 2026 | |
| 2026 Adjusted EPS | Reported | -0.3 | -0.27 | -0.23 | 1.5% | Raised | Guidance: -0.28 for 2026 | |
Q2 2026 Earnings Reported 1/6/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Net Sales | Reported | 312.00 Mil | 313.00 Mil | 314.00 Mil | 0.8% | Raised | Guidance: 310.50 Mil for 2026 | |
| 2026 Med Tech Net Sales Growth | Reported | 14.0% | 15.0% | 16.0% | 0 | Affirmed | Guidance: 15.0% for 2026 | |
| 2026 Med Device Net Sales Growth | Reported | 0.0% | 0.5% | 1.0% | ||||
| 2026 Gross Profit | Calculated | 166.92 Mil | 170.59 Mil | 174.27 Mil | Rev x Gross Margin | |||
| 2026 Gross Margin | Reported | 53.5% | 54.5% | 55.5% | 0 | Affirmed | Guidance: 54.5% for 2026 | |
| 2026 Adjusted EBITDA | Reported | 8.00 Mil | 9.00 Mil | 10.00 Mil | 12.5% | Raised | Guidance: 8.00 Mil for 2026 | |
| 2026 Adjusted EPS | Reported | -0.33 | -0.28 | -0.23 | 0 | Affirmed | Guidance: -0.28 for 2026 | |
Q1 2026 Earnings Reported 10/2/2025
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Net Sales | Reported | 308.00 Mil | 310.50 Mil | 313.00 Mil | 1.0% | Raised | Guidance: 307.50 Mil for 2026 | |
| 2026 Med Tech Net Sales Growth | Reported | 14.0% | 15.0% | 16.0% | 1.5% | Raised | Guidance: 13.5% for 2026 | |
| 2026 Gross Profit | Calculated | 164.78 Mil | 169.22 Mil | 173.72 Mil | Rev x Gross Margin | |||
| 2026 Gross Margin | Reported | 53.5% | 54.5% | 55.5% | 0 | Affirmed | Guidance: 54.5% for 2026 | |
| 2026 Adjusted EBITDA | Reported | 6.00 Mil | 8.00 Mil | 10.00 Mil | 45.4% | Raised | Guidance: 5.50 Mil for 2026 | |
| 2026 Adjusted EPS | Reported | -0.33 | -0.28 | -0.23 | -6.7% | Raised | Guidance: -0.3 for 2026 | |
Insider Activity
Updated 7/31/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Nighan, Warren JR | SVP Quality and Regulatory | Direct | Sell | 7312026 | 14.72 | 23,370 | 344,006 | 953,046 | Form |
| 2 | Weiss, Lawrence T | SVP, Chief Legal Officer | Direct | Buy | 10222025 | 11.81 | 10,000 | 118,100 | 1,105,381 | Form |
| 3 | Trowbridge, Stephen A | EVP and CFO | Direct | Buy | 10142025 | 11.16 | 890 | 9,932 | 2,863,980 | Form |
| 4 | Clemmer, James C | President and CEO | Direct | Buy | 10092025 | 11.15 | 10,000 | 111,500 | 9,840,198 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Nighan, Warren JR | SVP Quality and Regulatory | Direct | Sell | 7312026 | 14.72 | 23,370 | 344,006 | 953,046 | Form |
| 2 | Weiss, Lawrence T | SVP, Chief Legal Officer | Direct | Buy | 10222025 | 11.81 | 10,000 | 118,100 | 1,105,381 | Form |
| 3 | Trowbridge, Stephen A | EVP and CFO | Direct | Buy | 10142025 | 11.16 | 890 | 9,932 | 2,863,980 | Form |
| 4 | Clemmer, James C | President and CEO | Direct | Buy | 10092025 | 11.15 | 10,000 | 111,500 | 9,840,198 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.